Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 14/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.46 |
| ▸ | ATR | Q13535 | 2/20 | 0.41 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4584769 | 0.86 | ADORA2A (0.47) | ADORA2AADORA1ATR | |
| SCHEMBL4585113 | 0.84 | ADORA2A (0.49) | ADORA2AADORA1 | |
| SCHEMBL4584817 | 0.84 | ADORA2A (0.51) | ADORA2AADORA1ATRACVR1 | |
| SCHEMBL28758570 | 0.83 | ADORA2A (0.47) | ADORA2AADORA1 | |
| SCHEMBL4585332 | 0.83 | ADORA2A (0.48) | ADORA2AADORA1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4584514 | 0.83 | ADORA2A (0.50) | ADORA2AADORA1ATRACVR1 | |
| SCHEMBL4584074 | 0.83 | ADORA2A (0.50) | ADORA2AADORA1ATRACVR1 | |
| SCHEMBL4584106 | 0.82 | ADORA2A (0.47) | ADORA2AADORA1 | |
| SCHEMBL4584042 | 0.81 | ADORA2A (0.49) | ADORA2AADORA1 | |
| SCHEMBL4585043 | 0.80 | ADORA2A (0.49) | ADORA2AADORA1ATRACVR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7407961-B2 | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC. (JP) | 2008-08-05 | — | — | US | disclosed |
| CN-1871231-A | Pyrazine derivatives and pharmaceutical use thereof | ASTELLAS PHARMA INC (JP) | 2006-11-29 | — | — | CN | disclosed |
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113387-A1 | Pyrazine derivatives and pharmaceutical use thereof | ADORA2A, P2RX5, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ATR 3727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.